High-throughput Membrane Protein Array Technology

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Membrane proteins, which play a pivotal role in cell signaling and adhesion, have been the cornerstone of CAR-T cell therapy. They serve as targets for engineered CAR receptors, allowing specific recognition and elimination of diseased cells. However, the selection of the right membrane protein target is a critical factor in the success of CAR-T cell therapy.

High-throughput Membrane Protein Array Technology is a comprehensive approach that enables the rapid and systematic profiling of membrane proteins. It involves the creation of an array of membrane proteins, typically derived from disease-specific cells, and their subsequent assessment for binding specificity with CAR-T cells. This innovative technology offers a holistic and efficient platform for characterizing and validating CAR specificity.

Applications of High-Throughput Membrane Protein Array

Evaluating the recognition of the intended target.
Profiling the positive binding of CAR to human membrane proteins.
Furnishing data on the number, identities, and strength of cross-reactions.

The analysis of membrane protein data facilitates the determination of CAR target specificity, the exclusion of scFv with cross-reactivity, and the prediction of potential side effects associated with the proposed applications of CAR therapy.

Fig.1 Identified 6,718 human membrane proteins belong to the three major functional groups.¹

Key Features

Diverse Range of Human Membrane Proteins: Our membrane protein array is comprised of a vast collection of over 4,000 human membrane proteins, encompassing a comprehensive representation of most known membrane proteins.
Functional Membrane Proteins: The membrane proteins expressed in HEK293T or QT6 cells exhibit full functionality, maintaining their native conformation and essential post-translational modifications.
Comprehensive Binding Analysis: We have extensively examined numerous binding interactions utilizing soluble Fc-tagged proteins. The outcomes have been rigorously verified through highly sensitive high-throughput flow cytometry, ensuring data accuracy and reliability.
Stringent Validation Process: Positive targets initially identified in the screening process undergo a second titration analysis, which serves to reduce the occurrence of false positives. This approach not only enhances the credibility of the results but also optimizes the efficiency of subsequent validation and in-depth investigation, ultimately saving valuable time and resources.

Cross-reactivity screening represents a pivotal tool in evaluating the potential off-target effects of CAR therapies and is essential for reducing risks through a comprehensive safety validation process. Drawing upon our extensive experience in CAR-T immunotherapy development and antibody discovery, Creative Biolabs has pioneered the development of a cell-based high-throughput membrane protein array for CAR specificity screening and profiling.

Please contact us for more information about the different assays or services that are available to support your programs.

References

Almén MS, et al. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biology. 2009 Aug;7:50.
Zhang, S.; et al. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep 12, 10488 (2022).

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION